Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study

BACKGROUND: Bacillus coagulans MTCC 5856 has been marketed as a dietary ingredient, but its efficacy in diarrhea predominant irritable bowel syndrome (IBS) condition has not been clinically elucidated till date. Thus, a double blind placebo controlled multi-centered trial was planned to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Majeed, Muhammed, Nagabhushanam, Kalyanam, Natarajan, Sankaran, Sivakumar, Arumugam, Ali, Furqan, Pande, Anurag, Majeed, Shaheen, Karri, Suresh Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769834/
https://www.ncbi.nlm.nih.gov/pubmed/26922379
http://dx.doi.org/10.1186/s12937-016-0140-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769834/
https://www.ncbi.nlm.nih.gov/pubmed/26922379
http://dx.doi.org/10.1186/s12937-016-0140-6

Ejemplares similares